Advertisement

VirusDisease

, Volume 29, Issue 1, pp 19–26 | Cite as

Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options

  • Sayed Sartaj Sohrab
  • Mohd Suhail
  • Ashraf Ali
  • Ishtiaq Qadri
  • Steve Harakeh
  • Esam I. Azhar
Review Article

Abstract

Hepatitis C virus (HCV) is a common opportunistic pathogen especially among Human immunodeficiency virus (HIV) infected patients. Due to incongruous studies, the pathological effect of HCV on HIV induced disease are still not fully understood. While some studies have showed no effect of HCV on HIV infection, others reported a defined role of HCV in aggravating the rates of AIDS-related illnesses and mortality. The explanation of such variances may be due to the host immune response, viral genotypes, sub-type and quasi-species distribution. The factors that complicate the management of HIV/HCV patients are: (1) reduced HCV antibody production, (2) drug interactions, (3) liver disease and (4) different epidemiologic characteristics. However, it is abundantly clear that the morbidity and mortality caused by HCV have increased since the introduction of highly active antiretroviral therapy (HAART) against HIV. In this review, the consequence of HIV/HCV co-infection on host immune response, viral replication, disease progression, mortality and morbidity, viral load, persistence and current treatment options have been discussed. Based on the clinical studies, it is necessary to evaluate the effect of HCV therapy on HIV progression and to provide a fully active HCV treatment for patients receiving HIV treatment. In conclusion, it is recommended to provide fully active HAART therapy in combination with a known HCV therapy.

Keywords

Hepatitis C virus HIV/HCV co-infection HIV progression Direct acting antivirals Interferons 

Notes

Acknowledgements

Authors would like to gratefully acknowledge the facility provided by King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia.

References

  1. 1.
    AIDSinfo. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. 2016. http://www.aidsinfonihgov/guidelines.
  2. 2.
    Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010;51(5):1523–30.  https://doi.org/10.1002/hep.23509.CrossRefGoogle Scholar
  3. 3.
    Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT. Team ACTGS. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis. 2004;189(8):1472–81.  https://doi.org/10.1086/382959.CrossRefGoogle Scholar
  4. 4.
    Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Semin Liver Dis. 2012;32(2):130–7.  https://doi.org/10.1055/s-0032-1316468.CrossRefGoogle Scholar
  5. 5.
    Branch AD, Van Natta ML, Vachon M-L, Dieterich DT, Meinert CL, Jabs DA, et al. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis. 2012;55(1):137–44.  https://doi.org/10.1093/cid/cis404.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M. Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. J Infect Dis. 2010;202(6):889–93.  https://doi.org/10.1086/655784.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Cho H, Kikuchi M, Li Y, Nakamoto N, Amorosa VK, Valiga ME, et al. Induction of multiple immune regulatory pathways with differential impact in HCV/HIV coinfection. Front Immunol. 2014.  https://doi.org/10.3389/fimmu.2014.00265.Google Scholar
  8. 8.
    Cotte L, Braun J, Sogni P, Vincent C, Valantin M-A, Vittecoq D, Michelet C, Batisse D, Morlat P, Gervais A, Pawlotsky J-M, Aboulker J-P, Molina J-M. High end-of-treatment (EOT) response rate with telaprevir-PegIFN-RBV in treatment-experienced HIV coinfected patients with HCV genotype 1: ANRS HC26 TelapreVIH study. In: 64th Annual Meeting of the American Association for the Study of Liver Diseases. 2013.Google Scholar
  9. 9.
    De Lédinghen V, Barreiro P, Foucher J, Labarga P, Castéra L, Vispo ME, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008;15(6):427–33.  https://doi.org/10.1111/j.1365-2893.2007.00962.x.CrossRefGoogle Scholar
  10. 10.
    Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the C212 study. In: 14th European AIDs conference. 2013.Google Scholar
  11. 11.
    Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G. Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. J Clin Virol. 2011;52(4):367–9.  https://doi.org/10.1016/j.jcv.2011.08.020.CrossRefGoogle Scholar
  12. 12.
    EACS. European AIDS Clinical Society. Guidelines, Version 7.0. [online]. 2013. http://www.eacsocietyorg/Portals/0/Guidelines_Online.
  13. 13.
    Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58(6):873–9.  https://doi.org/10.1093/cid/cit799.CrossRefGoogle Scholar
  14. 14.
    García-Álvarez M, Berenguer J, Jiménez-Sousa MA, Pineda-Tenor D, Aldámiz-Echevarria T, Tejerina F, et al. Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: a cross-sectional study. Sci Rep. 2017;7:41516.  https://doi.org/10.1038/srep41516.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Global Health Observatory (GHO) data. http://www.who.int/gho/hiv/en/. Last accessed on 25.12.2017.
  16. 16.
    Gonzalez FA, Van den Eynde E, Perez-Hoyos S, Navarro J, Curran A, Burgos J, et al. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients. HIV Med. 2015;16(4):211–8.  https://doi.org/10.1111/hiv.12197.CrossRefGoogle Scholar
  17. 17.
    Gupta P, Liu B, Wu JQ, Soriano V, Vispo E, Carroll AP, et al. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. Virology. 2014;450–451:336–49.  https://doi.org/10.1016/j.virol.2013.12.026.CrossRefGoogle Scholar
  18. 18.
    Jabara CB, Hu F, Mollan KR, Williford SE, Menezes P, Yang Y, et al. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother. 2014;58(10):6079–92.  https://doi.org/10.1128/aac.03466-14.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.  https://doi.org/10.1056/NEJMoa1214854.CrossRefGoogle Scholar
  20. 20.
    Kaczmarek DJ, Kokordelis P, Krämer B, Glässner A, Wolter F, Goeser F, et al. Alterations of the NK cell pool in HIV/HCV co-infection. PLoS ONE. 2017;12(4):e0174465.  https://doi.org/10.1371/journal.pone.0174465.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology. 2009;137(3):795–814.  https://doi.org/10.1053/j.gastro.2009.06.040.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Kong L, Welge JA, Powell EA, Blackard JT. HIV infection of hepatocytes results in a modest increase in hepatitis C virus expression in vitro. PLoS ONE. 2014;9(2):e83728.  https://doi.org/10.1371/journal.pone.0083728.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.  https://doi.org/10.1136/gutjnl-2012-302062.CrossRefGoogle Scholar
  24. 24.
    Lambers FAE, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;25(17):F21–7.  https://doi.org/10.1097/QAD.0b013e32834bac44.CrossRefGoogle Scholar
  25. 25.
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401–8.  https://doi.org/10.1016/s1473-3099(13)70033-1.CrossRefGoogle Scholar
  26. 26.
    Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.  https://doi.org/10.1016/s0140-6736(13)62121-2.CrossRefGoogle Scholar
  27. 27.
    Liberto MC, Zicca E, Pavia G, Quirino A, Marascio N, Torti C, et al. Virological mechanisms in the coinfection between HIV and HCV. Mediators Inflamm. 2015;2015:320532.  https://doi.org/10.1155/2015/320532.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim K-A, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology. 2008;134(3):803–11.  https://doi.org/10.1053/j.gastro.2008.01.005.CrossRefGoogle Scholar
  29. 29.
    Luo X, Fan Y, Park I-W, He JJ. Exosomes are unlikely involved in intercellular Nef transfer. PLoS ONE. 2015;10(4):e0124436.  https://doi.org/10.1371/journal.pone.0124436.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Marco A, Esteban JI, Solé C, da Silva A, Ortiz J, Roget M, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 2013;59(1):45–51.  https://doi.org/10.1016/j.jhep.2013.03.008.CrossRefGoogle Scholar
  31. 31.
    Martin TCS, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013;27(16):2551–7.  https://doi.org/10.1097/QAD.0b013e32836381cc.CrossRefGoogle Scholar
  32. 32.
    Nakano T, Lau GMG, Lau GML, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2012;32(2):339–45.  https://doi.org/10.1111/j.1478-3231.2011.02684.x.CrossRefGoogle Scholar
  33. 33.
    Omland LH, Jepsen P, Weis N, Christensen PB, Laursen AL, Nielsen H, et al. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. J Viral Hepat. 2010;17(4):261–8.  https://doi.org/10.1111/j.1365-2893.2009.01175.x.CrossRefGoogle Scholar
  34. 34.
    Park I-W, Fan Y, Luo X, Ryou M-G, Liu J, Green L, et al. HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication. PLoS ONE. 2014;9(6):e99545.  https://doi.org/10.1371/journal.pone.0099545.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Parodi C, Belmonte L, Baré P, de Bracco MME, Ruibal-Ares B. Impact of human immune deficiency virus infection on hepatitis C virus infection and replication. Curr HIV Res. 2007;5(1):55–67.CrossRefPubMedGoogle Scholar
  36. 36.
    Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis. 2012;32(2):103–13.  https://doi.org/10.1055/s-0032-1316473.CrossRefGoogle Scholar
  37. 37.
    Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, et al. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. AIDS. 2013;27(12):1941–7.  https://doi.org/10.1097/QAD.0b013e328360ea1e.CrossRefGoogle Scholar
  38. 38.
    Rockstroh NM, Soriano V, Arastéh K, Guardiola J, Bhagani S, Mallolas J, Tural C, et al. Start verso4 phase 3 trial of faldaprevir plus pegylated interferon α-2a and ribavirin in patients with HIV and HCV genotype-1 co-infection. 64th annual meeting of the American Association for the Study of Liver Diseases. 2013.Google Scholar
  39. 39.
    Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med. 2012;13(2):127–31.  https://doi.org/10.1111/j.1468-1293.2011.00933.x.CrossRefGoogle Scholar
  40. 40.
    Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte A, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol. 2013;59(2):213–20.  https://doi.org/10.1016/j.jhep.2013.04.005.CrossRefGoogle Scholar
  41. 41.
    Sánchez C, Plaza Z, Vispo E, de Mendoza C, Barreiro P, Fernández-Montero JV, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. 2013;33(9):1357–62.  https://doi.org/10.1111/liv.12212.CrossRefGoogle Scholar
  42. 42.
    Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: an update. Hepatology. 2015;62(6):1871–82.  https://doi.org/10.1002/hep.28150.CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008;47(2):221–5.  https://doi.org/10.1097/QAI.0b013e31815d2f59.CrossRefGoogle Scholar
  44. 44.
    Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–27.  https://doi.org/10.1002/hep.26744.CrossRefGoogle Scholar
  45. 45.
    Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS. 2011;25(18):2197–208.  https://doi.org/10.1097/QAD.0b013e32834bbb90.CrossRefGoogle Scholar
  46. 46.
    Thein H-H, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91.  https://doi.org/10.1097/QAD.0b013e32830e6d51.CrossRefGoogle Scholar
  47. 47.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.  https://doi.org/10.1056/NEJMoa040842.CrossRefGoogle Scholar
  48. 48.
    Vispo E, Fernández-Montero JV, Labarga P, Barreiro P, Soriano V. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS. 2013;27(7):1187–8.  https://doi.org/10.1097/QAD.0b013e32835cb815.CrossRefGoogle Scholar
  49. 49.
    Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369(18):1715–25.  https://doi.org/10.1056/NEJMsa1214720.CrossRefPubMedCentralGoogle Scholar
  50. 50.
    Webster DP, Wojcikiewicz T, Keller M, Castelnovo D, Mistry H, Gilleece Y, et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS. 2013;24(3):179–83.  https://doi.org/10.1177/0956462412472317.CrossRefGoogle Scholar

Copyright information

© Indian Virological Society 2018

Authors and Affiliations

  • Sayed Sartaj Sohrab
    • 1
  • Mohd Suhail
    • 3
  • Ashraf Ali
    • 3
  • Ishtiaq Qadri
    • 3
  • Steve Harakeh
    • 1
  • Esam I. Azhar
    • 1
    • 2
  1. 1.Special Infectious Agents Unit (SIAU)King Fahd Medical Research Center, King Abdulaziz UniversityJeddahSaudi Arabia
  2. 2.Department of Medical Laboratory Technology, Faculty of Applied Medical SciencesKing Abdulaziz UniversityJeddahSaudi Arabia
  3. 3.King Fahd Medical Research CenterKing Abdulaziz UniversityJeddahSaudi Arabia

Personalised recommendations